Research
Hormonal
GLP-1 receptor agonists (GLP-1 RAs) are used to treat type 2 diabetes and obesity due to benefits in glycemic control, weight loss, and cardiovascular risk reduction.
Practitioners should consider GLP-1 RAs for managing type 2 diabetes and obesity.
StrongSupportsmedium confidence
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used to treat type 2 diabetes and obesity due to their benefits in glycemic control, weight loss, and cardiovascular risk reduction.
Why this rating
The claim is based on established clinical use and benefits.
Source
GLP-1 Receptor Agonists: Clinical Considerations and Risk Management for Patients Undergoing Ophthalmic Surgery
Caroline R. Baumal et al. · Ophthalmic surgery, lasers & imaging retina · 2026
DOI 10.3928/23258160-20260310-01
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →